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Abstract  54 
Background: Though NCCN recommends consideration of localized adjuvant radiation 55 
following clear-margin surgery for cutaneous squamous cell carcinoma (CSCC) with large 56 
caliber (≥0.1mm) nerve invasion (LCNI) and other high-risk features, only a single small study 57 
has compared surgery plus adjuvant radiation (S+ART) to surgical monotherapy (SM) for 58 
CSCC.  59 
Objectives: Compare surgery plus adjuvant radiation (S+ART) to surgical monotherapy (SM) 60 
for primary CSCCs with LCNI and other risk factors. 61 
Methods: Matched retrospective cohort study of primary CSCCs (matched on gender, age, 62 
immune status, type of surgery, diameter, differentiation, depth and LCNI) treated with S+ART 63 
versus SM. Subgroup analysis of CSCCs with LCNI wasperformed. 64 
Results: 62 CSCCs were included in matched analysis (S + ART: 31, SM: 31) and 33 in LCNI 65 
analysis (S+ART: 16, SM: 17). There was no significant difference in local recurrence (LR), 66 
metastasis, or death from disease in either analysis. Risk of LR was low (7, 8%) with 3 of the 67 
LRs being effectively treated upon recurrence. 68 
Limitations: Single academic center, non-randomized design. 69 
Conclusion: Adjuvant radiation did not improve outcomes compared to SM due to a low 70 
baseline risk of recurrence; although ART for named n rve invasion and LCNI of 3 or more 71 
nerves has been shown to improve outcomes in a prior study. Randomized studies are needed to 72 
define the subset of CSCC for whom adjuvant radiation has utility.   73 

















Introduction  75 
Approximately 3.7-5.2% of CSCCs will develop metastasis and 2-3.5% of patients will die from 76 
disease.1-4 While the primary treatment of high-risk tumors is surgical removal with complete 77 
circumferential peripheral and deep margin assessment (CCPDMA), adjuvant therapies are 78 
sometimes considered in cases thought to have a risk of recurrence or death.5 Adjuvant 79 
radiation (ART) is sometimes used following surgery with clear histologic margins for 80 
select cases of CSCC. The National Comprehensive Cancer Network (NCCN) includes ART as 81 
a consideration for margin-negative CSCCs with extensive, large (nerve caliber ≥0.1mm), or 82 
named-nerve involvement or if other high-risk features are present at the clinician’s 83 
discretion.5  84 
 85 
Despite these recommendations, data on the efficacy of ART for margin-negative CSCCs is 86 
limited. Prior studies have focused on CSCCs with perineural invasion (PNI); however, the 87 
majority do not compare radiation outcomes to tumors treated with surgery monotherapy (SM) 88 
and so the effect of radiation is difficult to quantify.6-11 One prior study of 102 tumors that 89 
compared S+ART to SM found longer recurrence- (94% vs. 25%, p=0.01) and disease-free (73% 90 
vs. 40%, p=0.05) 2-year survival in tumors with PNI of more than 2 nerves (n=30), respectively, 91 
but there was no difference in cases with PNI of 1-2 nerves.12 Whether tumors had clear surgical 92 


















Data on ART for high-risk CSCCs without PNI is very heterogenous due to lack of consensus on 95 
the definition of high-risk CSCC. A 2009 systematic review was unable to draw conclusions 96 
about ART efficacy due to insufficient data.13 A more recent analysis evaluated local recurrence 97 
(LR) following ART for 52 high-risk CSCCs with depth of invasion > 6mm or desmoplasia. 98 
While the study excluded gross residual tumor post-surgery, it included tumors with 99 
histologically positive margins (n=16).  LR-free survival was 96% (95% confidence interval, 90-100 
100%) at 2 years but there was no SM group for comparison.14  101 
 102 
Radiation therapy is associated with morbidity, high-cost, and can complicate future attempts at 103 
resection should recurrence occur. Thus, data evaluating its impact on outcomes in the adjuvant 104 
setting for node-negative CSCC is needed in order to utilize radiation appropriately. The aim of 105 
this study was to perform a matched analysis of the impact of ART on completely-resected 106 
primary CSCC. Since large-caliber (≥0.1mm in caliber) nerve invasion (LCNI) is an indicat on 107 
to consider ART per NCCN guidelines and there is data to support improved outcomes in tumors 108 
with LCNI, but not small caliber PNI,5,12 a subgroup analysis of cases with LCNI was also 109 
performed utilizing controls without PNI.  110 
 111 
Methods 112 
Data Collection 113 
The study was approved by Partners Human Research Committee. Patients with CSCC 114 
diagnosed at Brigham and Women’s Hospital (BWH) from 1/1/2000-12/31/2017 were identified 115 

















noncutaneous SCC, anogenital SCC, in situ CSCC, and recurrent CSCC were excluded. Medical 117 
records of all eligible patients were reviewed for primary tumor data, outcome data [including 118 
local recurrence (LR), nodal metastasis (NM), distant metastasis (DM), and disease-specific 119 
death (DSD)], and types of treatment performed (including surgical approach and adjuvant 120 
therapy). Cases that received localized radiation underwent additional chart review for the 121 
following information: radiation modality, dose, fractions, dates that treatment was performed, 122 
and reason for ART. Only primary tumors with clear histologic margins following surgical 123 
excision (either wide local excision or Mohs micrographic surgery (MMS)) were included.  124 
 125 
Matched Analysis 126 
Primary tumors treated with surgical excision with clear surgical margins and ART (S+ART) 127 
were identified. Exact matching was used to select tumors treated with surgical excision 128 
monotherapy with clear surgical margins (SM). Case pairs were matched on gender, age (+/- 10 129 
years), immune status, type of surgical treatment, diameter (≥ 2cm vs. <2cm), differentiation 130 
(poor vs. well or moderate), depth of invasion (beyond subcutaneous fat vs. 131 
dermis/subcutaneous fat), and LCNI (present vs. absent). Tumors where controls could not 132 
be identified were excluded from analysis.  133 
 134 
Large Caliber Nerve Invasion (LCNI) Analysis 135 
Since LCNI is the most common indication for ART and a number of these tumors treated with 136 
ART could not be matched due to the strict matching criteria, LCNI tumors were analyzed 137 

















analysis, stratified by whether ART was used (including 6 cases contained in the matched 139 
analysis above).  140 
 141 
Statistical Analyses 142 
Patient and tumor characteristics were analyzed using descriptive statistics and frequency 143 
tabulation. For the matched analysis, outcomes of interest were analyzed by tumor pair and 144 
McNemar’s Test was used to determine whether there was a difference in L , NM, DM. For the 145 
LCNI cohort analysis, Chi-square and Fisher’s exact tests were used to determine whether there 146 
was a difference in LR, NM, DM, and DSD. Multivariable and survival analyses were not 147 
performed due to small number of outcomes and lack of significance on univariate analysis.  148 
 149 
All reported p-values were two-sided with type I error (α) of <0.05 considered to be statistically 150 
significant. Statistical analyses were performed using Stata version 14.0 (StataCorp, College 151 
Station, TX).  152 
 153 
Results 154 
Matched Case Analysis 155 
Forty-one CSCCs treated with surgical excision with clear margins and ART were identified of 156 
which 31 were able to be matched to similar cases a per criteria described in methods (table 1). 157 
There was no statistical difference in gender, age,immune status, diameter, depth of invasion, 158 
large caliber PNI, differentiation, type of surgical treatment (i.e. excision vs. MMS), and tumor 159 
location in S+ART vs. SM groups. Details on the patient and tumor risk factors for cases in the 160 

















tumors in the radiation group had lymphovascular invasion (LVI; S+ART 4 (13%) vs. SM 1 162 
(3%), p=0.4). There was a statistically significant difference in median follow-up time (S+ART 163 
49.5 (SD 32.8) vs. SM 32.9 (SD 27.3), p=0.03). Based on the American Joint Committee on 164 
Cancer (AJCC) 8th edition staging system for CSCC of the head and neck, there was no 165 
difference in tumor stages. The majority of tumors in both groups were BWH T2b (S+ART 20 166 
(65%) vs. SM 21 (68%)). 167 
 168 
In the S+ART group, the reason for radiation included perineural invasion (9, 29%), multifocal 169 
infiltrative tumor (9, 29%), deeply invasive tumor t  bone, cartilage, parotid, or fascia (8, 26%), 170 
lymphovascular invasion (4, 13%), and no epidermal connection (1, 3%). Details of the radiation 171 
treatment were available for 28 (90%) patients with all receiving localized radiation only. 172 
Twenty-seven (96%) patients completed their planned radiation treatment which ranged from 39-173 
70 Gy total. Three patients received chemoradiation consisting of cisplatin (dose not available) in 174 
1 patient. The other two received carboplatin 1-1.5auc + paclitaxel 30mg/m2 for 2 and 4 weeks 175 
during the course of ART. One of the patients discontinued the chemotherapy due to 176 
hospitalization and one switched to cetuximab 250mg/m2 for 1 week due to pancytopenia. In 177 
terms of acute radiation toxicities, most patients experienced grade 1 or 2 skin erythema. One 178 
(3%) experienced grade 3 skin erythema and 4 (13%) experienced grade 1 or 2 mucositis. Two 179 
patients developed late radiation toxicities; 1 (3%) had recurrent cellulitis and 1 (3%) had 180 
chronic pain.  181 
 182 
Clinical outcomes for the matched-case analysis are hown in table 3. A total of 4 tumors 183 

















difference in LR (S+ART 3 (10%) vs. SM 1 (3%), p=0.3), NM (S+ART 1 (3%) vs. SM 0 (0), 185 
p=0.3), DM (S+ART 1 (3%) vs. SM 0 (0), p=0.3), and DSD (S+ART 2 (6%) vs. SM 0 (0), 186 
p=0.2). Of the 3 LRs in the S+ART cohort, 1 was treated with MMS and had no further 187 
recurrences after 84 months of follow up, 1 patient developed an inoperable recurrence on the 188 
scalp and died of local disease 6 weeks after diagnosis of the recurrence, and 1 patient developed 189 
an LRs on the scalp as well as in transit metastase, NM, and DM and died of disease 5 months 190 
after diagnosis of the recurrence. The LR in the SM cohort was treated with a WLE with a 191 
positive deep margin and salvage radiation. The pati nt developed NM and DM 9 months later 192 
and died of disease 11 months after diagnosis of the recurrence. Of note, one patient in the 193 
S+ART group died from a second primary CSCC (not part of the study) diagnosed 6 years after 194 
the study tumor and did not receive radiation. The study tumor had no evidence of recurrence 81 195 
months after diagnosis when the patient died of the o r CSCC so the study tumor was recorded 196 
as no LR, NM, or DSD.  197 
 198 
LCNI Analysis 199 
Thirty-three tumors were included in the LCNI analysis, of which 16 (48%) received S+ART 200 
and 17 underwent SM (52%) (table 2). There was no difference in follow up time, 201 
immunosuppression, tumor location, tumor diameter, d pth of invasion, histologic 202 
differentiation, LVI, primary tumor treatment, adjuvant chemotherapy, or AJCC 8 tumor stage. 203 
The SM was 10 years older and 40% more male than the S+ART group, though these were not 204 
statistically significant differences between the groups.  There was a statistically significant 205 

















comprising 41% of the SM group and 0% of the S+ART group (p=0.01). Thus, all cases in the 207 
S+ART group had another prognostic risk factor besid s LCNI.  208 
 209 
Table 3 includes the clinical outcomes for the LCNI analysis based on treatment. A total of 3 210 
tumors developed poor outcomes (LR (2), LR+DSD (1)). Although there was no statistically 211 
significant difference in any outcome, more cases in the SM group had LRs [S+ART 0 (0) vs. 212 
SM 3 (18%), p=0.2)]. One of the 3 patients developed multiple in transit metastases treated with 213 
excision and ART, with no evidence of recurrence at 9 months. The second patient developed a 214 
LR requiring orbital exenteration. A second recurrence was treated with palliative radiation, and 215 
resulted in death shortly thereafter. The final patient had a LR successfully treated with MMS 216 
with no evidence of recurrence 36 months later.  217 
 218 
Description of Cases with Poor Outcomes  219 
Table 4 summarizes the characteristics and outcomes f the cases with poor outcomes in both the 220 
matched case and LCNI analyses.  221 
 222 
Discussion 223 
To the best of our knowledge, this study is the first to compare S+ART to SM for node-negative 224 
primary CSCCs with clear surgical margins, the second f r cases with PNI, the first for cases 225 
with LCNI, and the first to conduct a matched analysis of multiple prognostic factors. There was 226 
no difference in outcomes in either the matched-case or LCNI analyses.  The results are in 227 
keeping with the other study of PNI in that a (non-significant) trend was found for less LR in 228 

















group accounting for the trend were effectively trea ed at the time of LR.  In the 89 total cases 230 
reported herein, only 7 (8%) had a local recurrence, of which 3 were successfully salvaged at the 231 
time of LR. The null findings herein reflect a low baseline risk of poor outcomes for high-stage 232 
primary CSCCs with clear histologic margins. Even when LR occurs, most patients still appear 233 
to be curable.  Although this is a small study, a post-hoc power analysis shows that the matched 234 
analysis was adequately powered to detect a 50% reduction in LR, the effect of ART on 235 
recurrence rates in epithelioid tumors, since the sample size needed is 53 total tumors and the 236 
analysis include 62 tumors. The LCNI analysis was powered to detect a 60% reduction, so a 237 
larger study is needed to assess smaller reductions.  238 
 239 
Margin status following surgery greatly impacts outcomes. CCPDMA (en face sectioning with 240 
nearly 100% margin assessment, e.g. Mohs excision) is recommended by the NCCN for high-241 
risk CSCCs (as is wide excision if it can be closed primarily).15 A systematic review comparing 242 
standard assessment (approximately 1% of margin histologically evaluated) to CCPDMA found 243 
a higher risk of recurrence for keratinocytic carcinomas with PNI treated with standard 244 
assessment (23%) versus CCPDMA (10%, p=0.0004).16 A recent study of 647 CSCCs treated 245 
with only MMS found that 10%, 17%, 5%, and 5% of 145 high-stage CSCCs (defined as BWH 246 
T2b/T3) the risk of LR was only 10%.17 ART for epithelial tumors is offered when the risk of 247 
recurrence exceeds 15-20%. Since radiation is not expected to impact nodal or distant metastasis, 248 
a 10% LR risk for high-stage CSCC may not be high enough for radiation to significantly impact 249 


















It is possible that if a subset of CSCCs with a greater risk of LR were identified, radiation may be 252 
better able to influence outcomes. Meanwhile, since the risk of poor outcomes is elevated for 253 
high-stage CSCC, it is reasonable to monitor such tmors with close clinical and radiologic 254 
surveillance.18,19 Though the data presented herein do not support ART solely on the basis of 255 
PNI, none of the cases had named nerve and extensive PNI was not routinely recorded given the 256 
lack of a clear definition. Therefore, it is possible that ART may impact outcomes with more 257 
extensive nerve invasion. Currently in our practice, w  utilize ART for named nerve invasion, 258 
LCNI with 3 or more nerves, as supported by the single comparative study of more advanced 259 
PNI,12 or when clear surgical margins are in question. A multidisciplinary discussion is 260 
recommended for very aggressive or recurrent tumors in order to select cases that may benefit 261 
from adjuvant treatment.  262 
 263 
Despite the findings presented herein, it is important o recognize that there is good evidence to 264 
support radiation for node-positive CSCCs. A retrospective study of 122 patients with CSCCs 265 
metastatic to cervical lymph nodes found improved 5-year disease free survival (74% vs. 34%, 266 
p=0.001) and 5-year overall survival (66% vs. 27%, p=0.003) in patients who underwent surgery 267 
and radiation compared to surgery alone.20 Another study found lower locoregional recurrence 268 
(20% vs. 43%, p values not reported) and improved 5-year disease-free survival rate (73% vs. 269 
54%; p=0.004) in 167 patients with metastatic CSCC of the head and neck (including parotid 270 
metastases) who received S+ART versus SM, respectively.21 271 
 272 
This study is subject to limitations. In the matched-case analysis, the shorter mean follow-up 273 

















poor outcomes. However, average follow up time was more than 2 years and 85-96% of 275 
recurrences occur within 2 years of treatment, so the impact of the differential follow-up 276 
was likely minimal.12,22  Since the study is retrospective, there were no standard inclusion 277 
criteria for tumors receiving ART. However, the cohort reflects current clinical scenarios where 278 
ART is utilized in CSCC. Radiation treatment fields were not reviewed and there was 279 
variation in treatment protocols. However, in the matched analysis there was only 1 LR in 280 
the SM group indicating surgery alone may be sufficient, which would make variation in 281 
radiation protocols a moot point. In the LCNI analysis, those in the surgical monotherapy 282 
group were 10 years older and 40% more male (both are factors associated with worse 283 
CSCC outcomes).23 However, this group also had lower stage disease (41% were BWH low-284 
stage vs none in ART group).  Such differences likely balanced each other and are unlikely 285 




ART for node- and margin-negative primary CSCC did not improve outcomes compared to SM, 290 
due to low baseline risk of poor outcomes in primary CSCCs with clear histologic margins. The 291 
18% local recurrence risk in LCNI cases treated with SM is relatively high, but represents only 3 292 
cases of recurrence, 2 of which were successfully treated at time of recurrence. Randomized 293 
trials are needed to define which CSCC patients benefit from ART. Meanwhile, the present 294 
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Surgery + ART 
(n=31) p-value* 
Age at diagnosis, mean (SD), y 73.9 (11.9) 69.1 (12.8) 0.1† 
Follow-up time, median (IQR), months 32.9 (27.3) 49.5 (32.8) 0.03† 
Sex, n (%) 
       Female 9 (29) 9 (29) 1.0 
    Male 22 (71) 22 (71) 
 Immunosuppression, n (%) 
      No  18 (58) 21 (68) 0.6 
    Yes 13 (42) 10 (32) 
 Tumor location, n (%) 
       Ear and lip 5 (16) 7 (23) 0.6 
    Head and neck 19 (61) 18 (58) 
     Trunk 4 (13) 4 (13) 
     Arms, hands, legs, feet 3 (10) 2 (6) 
 Tumor diameter 
       <2.0 cm 12 (39) 12 (39) 1.0 
    ≥2.0 cm 19 (61) 19 (61) 
 Depth of invasion 
      Dermis/Subcutaneous fat 14 (45) 14 (45) 1.0 
   Beyond Subcutaneous fat 17 (55) 17 (55) 
 Histologic differentiation 
      Well and moderate 15 (48) 15 (48) 1.0 
    Poor 16 (52) 16 (52) 
 Perineural invasion 
       No 20 (65) 13 (42) 0.1 
    Yes 11 (35) 18 (58) 
 Diameter of perineural invasion  
     <0.1 mm or no perineural invasion 25 (81) 25 (81) 1.0 
   ≥0.1 mm 6 (19) 6 (19) 
 LVI 
      No 30 (97) 27 (87) 0.4 
   Yes 1 (3) 4 (13) 
 Primary treatment, n (%) 
     Surgical excision 9 (29) 10 (32) 1.0 
   Mohs surgery 22 (71) 21 (68) 
 Adjuvant chemotherapy 
      No 31 (100) 28 (90) 0.2‡ 
   Yes 0 (0) 3 (10) 
 AJCC-8 tumor stage 
      T1 5 (16) 3 (10) 0.9 
   T2 2 (6) 1 (3) 
    T3 16 (52) 20 (65) 
    T4 1 (3) 1 (3) 


















BWH tumor stage 
      T1 




7 (23) 0.4 
   T2b 21 (68) 20 (65) 
    T3 1 (3) 4 (13) 
 Indication for ART 
    Perineural invasion 
    Multifocal infiltrative Tumor 
    Deeply invasive to bone, cartilage,    
         parotid, or fascia 
    Lyphovascular invasion 






















   AJCC, American Joint Committee on Cancer; BWH, Brigham and Women's Hospital; SD, standard deviation; 
ART, adjuvant radiation therapy. 
*Chi-square statistics unless otherwise specified 
 §AJCC-8 staging only applies to CSCC on the head and neck. "Not applicable" indicates tumors on non-head 
and neck locations. 
†Student t-test p-value 
   ‡Fisher exact test p-value 
 







































Surgery + ART 
(n=16) p-value* 
Age at diagnosis, mean (SD), y 73.5 (15.2) 63.8 (16.7) 0.09† 
Follow-up time, median (IQR), months 27.3 (21.6) 43.3 (30.9) 0.09† 
Sex, n (%) 
       Female 5 (29) 9 (56) 0.2 
    Male 12 (71) 7 (44) 
 Immunosuppression, n (%) 
      No  9 (53) 11 (69) 0.5 
    Yes 8 (47) 5 (31) 
 Tumor location, n (%) 
       Ear and lip 1 (6) 4 (25) 0.5 
    Head and neck 12 (71) 10 (63) 
     Trunk 2 (12) 1 (6) 
     Arms, hands, legs, feet 2 (12) 1 (6) 
 Tumor diameter 
       <2.0 cm 12 (71) 8 (50) 0.3 
    ≥2.0 cm 5 (29) 8 (50) 
 Depth of invasion 
      Dermis/Subcutaneous fat 9 (53) 7 (44) 0.7 
   Beyond Subcutaneous fat 8 (47) 9 (56) 
 Histologic differentiation 
      Well and moderate 16 (94) 12 (75) 0.2 
    Poor 1 (6) 4 (25) 
 LVI 
      No 17 (100) 16 (100) 1.0 
   Yes 0 (0) 0 (0) 
 Primary treatment, n (%) 
     Surgical excision 0 (0) 0 (0) 1.0 
   Mohs surgery 17 (100) 16 (100) 
 Adjuvant chemotherapy 
      No 17 (100) 16 (100) 1.0‡ 
   Yes 0 (0) 0 (0) 
 AJCC-8 tumor stage 
      T1 0 (0) 0 (0) 0.7 
   T2 0 (0) 0 (0) 
    T3 13 (76) 14 (88) 
    T4 0 (0) 0 (0) 
    Not applicable§ 4 (24) 2 (12) 
 BWH tumor stage 
      T1 




0 (0) 0.01 
   T2b 10 (59) 15 (94) 


















    AJCC, American Joint Committee on Cancer; BWH, Brigham and Women's Hospital; SD, standard deviation; 
PNI, perineural invasion; ART, adjuvant radiation therapy 
*Chi-square statistics unless otherwise specified 
 §AJCC-8 staging only applies to CSCC on the head and neck. "Not applicable" indicates tumors on non-head 
and neck locations. 
†Student t-test p-value 
   ‡Fisher exact test p-value 
 


















Table 3. Clinical outcomes  
 
Matched-Case Tumors 
 Surgical monotherapy (n=31) Surgery + ART (n=31) p-value* 
Local recurrence, n (%) 1 (3) 3 (10) 0.3 
Nodal metastases, n (%) 0 (0) 1 (3) 0.3 
Distant metastases, n (%) 0 (0) 1 (3) 0.3 
Disease-specific death, n (%) 0 (0) 2 (6) 0.2 
Large Caliber PNI Tumors 
 Surgical monotherapy (n=17) Surgery + ART (n=16) p-value† 
Local recurrence, n (%) 3 (18) 0 (0) 0.2 
Nodal metastases, n (%) 0 (0) 0 (0) 1.0 
Distant metastases, n (%) 0 (0) 0 (0) 1.0 
Disease-specific death, n (%) 1 (6) 0 (0) 1.0 
 
Abbreviations: ART, adjuvant radiation therapy; PNI, perineural invasion 
*p-value determined using McNemar’s Test 
†p-value determined using Fisher’s Exact Test 
  

















Table 4. Characteristics and outcomes of cases from the matched- ase and LCNI analyses which developed a poor outcome.   
 




High-Risk Factors Primary Tumor 
Treatment 
Outcomes Disease Free 
Survival (months) 




Diffuse large T cell 
lymphoma 
Cheek T2B/T3 Poor-Differentiation 
Tumor Diameter (3.0cm) 
Depth of invasion (fascia) 






Scalp T3/T3 Poor-Differentiation 
Tumor Diameter (4.0cm) 
Depth of invasion (bone) 
MMS 
ART with electrons 
(55Gy in 20 fractions) 





Cheek T2B/T3 Tumor Diameter (4.0cm) 
Depth of Invasion (Parotid) 
MMS 
ART (60Gy in 30 
fractions) 
LR 8  
Matched Case 
Treated with SM 
64-year-old M 
Lung Transplant 
Ear T2B/T3 Tumor Diameter (2.5cm) 
Depth of Invasion 
(Perichondrium) 





Scalp T2B/T3 Poor-Differentiation 
Depth of Invasion (fascia) 
LVI 
MMS 
ART with electrons 






Treated with SM 
77-year-old M Scalp T2B/T3 Poor-Differentiation 
Depth of Invasion (Fascia) 
MMS  25  
4 
 
74-year-old M Scalp T3/T4A Tumor Diameter (4.0cm) 









Treated with SM 
73-year-old M Forehead T2B/T3 Tumor Diameter (2.3cm) 
Depth of Invasion (Muscle) 
MMS  20  
Poor Outcomes from Large Caliber PNI Analysis 













Scalp T2B/T3 Tumor Diameter (2.7cm) 
Depth of Invasion (Galea) 







92-year-old M Scalp T2B/T3 Tumor Diameter (3.8cm) 
Depth of Invasion (Galea) 
Large-Caliber PNI 
MMS LR 5  
 Abbreviations: S+ART, surgery and adjuvant radiation; SM, surgery monotherapy, M, male; MMS, Mohs micrographic surgery; ART, adjuvant radiation; LR, 
local recurrence; DM, distant metastasis; DSD, disease specific death; PNI, perineural invasion; BWH, Brigham and Women’s Hospital; AJCC8, American Joint 


















Table 5. Risk factors for SM+ART cases from the matched-case analysis.  
Case # Diameter (cm) Differentiation Depth of Invasion Perineural Invasion Other Factors 
1 6.2 Poor Bone PNI (unknown caliber) Renal transplant recipient  
2 1.7 Poor Muscle Possible focus of PNI  Required 3 Mohs stages to clear 
3 0.4 Poor Muscle Multifocal smaller caliber PNI Foci of single cell infiltration 
4 4.0 Poor Unknown None  
5 4.2 Poor Subcutaneous fat PNI (unknown caliber) CLL 
6* 4.0 Moderate Parotid None Renal transplant recipient 
7 3.4 Poor Subcutaneous fat/14mm None  
8* 4.0 Well Bone None  
9* 1.5 Poor Fascia None Lung transplant recipient 
LVI 
10 2.4 Moderate Parotid PNI (unknown caliber) Renal transplant recipient 
LVI 
11 2.5 Poor Muscle None  
12 0.7 Poor Dermis PNI (unknown caliber) Spindle cell histology 
Required 3 Mohs stages to clear 
13 2.8 Poor Subcutaneous fat/6mm None LVI  
14 4.0 Poor Dermis PNI (unknown caliber)  
15 3.0 Moderate Muscle PNI (unknown caliber)  
16* 1.3 Poor Dermis Foci suspicious for PNI Desmoplastic 
Single cell infiltrative 
17 2.0 Well Subcutaneous Fat PNI (0.2mm)  
18 0.9 Well Muscle PNI (0.125mm)  
19 0.4 Well Muscle PNI (0.2mm) Renal transplant recipient 
20 3.6 Moderate Galea PNI (0.14mm)  
21 3.0 Poor Subcutaneous fat None LVI  
22 2.5 Moderate Cartilage/5mm None Crohn’s disease 
23 0.5 Poor Dermis None No epidermal connection 
24 3.6 Moderate Cartilage None  
25 1.0 Poor Dermis None Systemic lupus erythematosus 
26 3.0 Well Subcutaneous fat PNI (0.125mm)  
27 1.1 Well Galea PNI (0.08mm)  
28 3.0 Moderate Unknown None CLL 
Close but clear margins 
29 4.6 Moderate Galea None  
30 4.0 Poor Bone PNI (unknown caliber) CLL 
31 0.8 Well Muscle PNI (0.2mm)  































• Radiation is sometimes used after surgery for cutaneous squamous cell carcinoma. 
• Outcomes were the same with or without radiation in a matched analysis and subgroup 
analysis of cases with nerve invasion. Only 8% of cases recurred. All but 3 were still 
curable. Studies are needed determining which patients need radiation. 
 
